FY2026 EPS Estimates for MannKind Cut by Leerink Partnrs

MannKind Corporation (NASDAQ:MNKD) – Equities researchers at Leerink Partnrs lowered their FY2026 EPS estimates for MannKind in a report issued on Wednesday, June 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will earn $0.14 per share for the year, down from their prior estimate of $0.16. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

A number of other analysts have also issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of MannKind in a research report on Thursday, February 27th. Mizuho began coverage on shares of MannKind in a research report on Thursday, April 10th. They issued an “outperform” rating and a $12.00 price target for the company. Finally, Wall Street Zen raised shares of MannKind from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $10.33.

MannKind Trading Up 1.6%

MNKD stock opened at $3.81 on Thursday. MannKind has a one year low of $3.63 and a one year high of $7.63. The firm has a market capitalization of $1.16 billion, a PE ratio of 38.10 and a beta of 1.02. The firm has a 50-day moving average of $4.41 and a two-hundred day moving average of $5.29.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. MannKind had a net margin of 10.12% and a negative return on equity of 32.41%. The company had revenue of $78.35 million during the quarter, compared to analyst estimates of $75.86 million. During the same period in the prior year, the firm earned $0.05 earnings per share. The business’s quarterly revenue was up 18.1% on a year-over-year basis.

Hedge Funds Weigh In On MannKind

A number of hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in MannKind by 4.4% in the first quarter. Rhumbline Advisers now owns 399,033 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 16,807 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of MannKind by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company’s stock valued at $3,374,000 after purchasing an additional 53,202 shares during the period. Millennium Management LLC raised its position in shares of MannKind by 68.9% in the first quarter. Millennium Management LLC now owns 5,822,590 shares of the biopharmaceutical company’s stock valued at $29,288,000 after purchasing an additional 2,375,198 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MannKind by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company’s stock valued at $1,059,000 after purchasing an additional 6,079 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of MannKind by 5.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 2,029,319 shares of the biopharmaceutical company’s stock valued at $10,207,000 after purchasing an additional 110,945 shares during the period. Institutional investors and hedge funds own 49.55% of the company’s stock.

Insider Buying and Selling

In related news, Director Steven B. Binder sold 80,144 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $4.69, for a total value of $375,875.36. Following the transaction, the director now owns 1,006,611 shares in the company, valued at approximately $4,721,005.59. This represents a 7.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP David Thomson sold 32,179 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $4.68, for a total value of $150,597.72. Following the completion of the transaction, the executive vice president now owns 772,427 shares in the company, valued at $3,614,958.36. This represents a 4.00% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 190,831 shares of company stock worth $846,298. Insiders own 2.70% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.